Antiviral Testing Facility

The Burnet Antiviral Testing facility has the capacity to evaluate chemical agents for inhibitory activity against HIV and herpes simplex (HSV) type 1 and 2 viruses in cell culture assays.

This enables the development of new molecules that may lead to better  treatments and/or prophylactics for these chronic infections.

All work undertaken by the facility uses principles outlined in the FDA guidelines for Antiviral Product Development.

Contact: [email protected]